James M. Fujitaki

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Mark D. Erion, Edward E. Cable, Bruce R. Ito et al. · Proceedings of the National Academy of Sciences · 2007 · 262 citations · Full text

Pharmacotherapy, Fatty Liver Disease, Metabolic Syndrome +18

The broad spectrum antiviral agent ribavirin inhibits capping of mRNA

Biswendu B. Goswami, Ernest Borek, Opendra K. Sharma et al. · Biochemical and Biophysical Research Communications · 1979 · 207 citations

Viral Replication, Medicine, Antiviral Drug Development +6

Liver-Targeted Drug Delivery Using HepDirect Prodrugs

Mark D. Erion, Paul D. van Poelje, Deidre A. MacKenna et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 117 citations

AICA‐Riboside: Safety, Tolerance, and Pharmacokinetics of a Novel Adenosine‐Regulating Agent

Ross Dixon, James T. Gourzis, Daniel McDermott et al. · The Journal of Clinical Pharmacology · 1991 · 105 citations

Iv Administration, Heart Failure, Active Drug +13

Discovery of Potent and Specific Fructose-1,6-Bisphosphatase Inhibitors and a Series of Orally-Bioavailable Phosphoramidase-Sensitive Prodrugs for the Treatment of Type 2 Diabetes

Qun Dang, Srinivas Rao Kasibhatla, K. Raja Reddy et al. · Journal of the American Chemical Society · 2007 · 95 citations

Pharmaceutical Science, Glycobiology, Glucose Production +17